购物车
全部删除
您的购物车当前为空
Akt1-IN-8 (Compound JL18) 是一种高效且口服生物利用度为41%的AKT1激酶抑制剂,其IC50值为8.8 nM。它在PC-3前列腺癌细胞中显示出显著的抗增殖效果,IC50值为3.0 μM。Akt1-IN-8 可降低磷酸化GSK3β的水平。

Akt1-IN-8 (Compound JL18) 是一种高效且口服生物利用度为41%的AKT1激酶抑制剂,其IC50值为8.8 nM。它在PC-3前列腺癌细胞中显示出显著的抗增殖效果,IC50值为3.0 μM。Akt1-IN-8 可降低磷酸化GSK3β的水平。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
Akt1-IN-8 相关产品
| 产品描述 | Akt1-IN-8 (Compound JL18) is a potent AKT1 kinase inhibitor with oral bioavailability of 41% and an IC50 value of 8.8 nM. It exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 also reduces phosphorylated GSK3β levels. |
| 靶点活性 | Akt1:8.8 nM |
| 分子量 | 551.278 |
| 分子式 | C21H25Br2N7O |
| CAS No. | 2247688-87-3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容